首页> 外国专利> AGENT FOR EARLY CONTRAST DETECTION OF MALIGNANT PROLIFERATION CENTERS WITH FEEDING VESSELS, BOUNDARIES OF DIFFUSE INFILTRATION AND DETERMINATION OF STAGES OF THEIR DEVELOPMENT IN DYNAMICS

AGENT FOR EARLY CONTRAST DETECTION OF MALIGNANT PROLIFERATION CENTERS WITH FEEDING VESSELS, BOUNDARIES OF DIFFUSE INFILTRATION AND DETERMINATION OF STAGES OF THEIR DEVELOPMENT IN DYNAMICS

机译:早期对比检测带有进食容器的恶性增殖中心,扩散扩散的边界和确定其动态发展阶段的代理商

摘要

FIELD: medicine.;SUBSTANCE: group of inventions relates to experimental medicine, radiation diagnostics and pharmacology and can be used as an early contrast magnetic resonance tomographic (CMRT) detecting centres of malignant proliferation (CMP) and determining the stages of their development in vivo in dynamics, as well as method CMRT detecting CMP with feeding vessels and an expanding border of diffuse infiltration of malignant cells (MC) into normal tissues in experiment. Agent contains an aqueous sol of ferrimagnetic nanoparticles of citrateferrite of general formula (Fe3O4+)m⋅(C6H7O7-)n. First method involves synthesis of ferrimagnetic nanocrystals of non-stoichiometric magnetite, etching the obtained ferrimagnetic nanocrystals with 36 % hydrochloric acid to obtain an aqueous sol of nanocrystals of general formula from (1.05Fe2+O⋅1.85Fe3+2O3⋅0.1Fe3+OCl)m to (1.15Fe2+O⋅1.75Fe3+2O3⋅0.1Fe3+OCl)m and coating the obtained nanocrystals in aqueous ash with citrate anions. Second method involves intravenous administration to laboratory animals of an aqueous sol of compounds of general formula (Fe3O4+)m⋅(C6H7O7-)n for 10 min – 75 h before CMRT scanning of the examined region and primary intravenous introduction of Magnevist® 3–9 minutes before CMRT scanning; carrying out CMRT scanning tissues in modes of producing T1 B, T2 B spin echo, T2 B echo gradient and T*2 B echo gradient; repeated intravenous introduction of Magnevist® 3–5 minutes before CMRT scanning the analyzed region with visualizing the boundaries of diffuse infiltration of the MC into normal tissues and secondary intravenous introduction of an aqueous sol of compounds of general formula (Fe3O4+)m⋅(C6H7O7-)n 5–10 minutes before CMRT scanning the examined region with subsequent visualization of the contrast image of the diffuse infiltration of the MC into normal tissues; carrying out CMRT scanning tissues in modes of producing T1 B, T2 B spin echo, T2 B echo gradient and T*2 B echo gradient; inidentification CMP with feeding vessels and borders of diffuse infiltration of MC into normal tissues by changes of intensity of voxels in investigated area.;EFFECT: group of inventions provides selecting a combination of a negative and a positive contrast agent and optimal parameters CMRT scanning an animal's body for detecting CMP, early CMRT detection CMP and determining the developmental stages CMP in dynamics in experiment on immunocompetent animals with transplantable malignant tumors by synthesis of declared agent administered in different periods to CMRT scanning.;9 cl, 14 dwg, 2 tbl, 8 ex
机译:领域:发明领域本发明涉及实验医学,放射诊断学和药理学,并且可以用作早期造影磁共振层析成像(CMRT)检测恶性增殖(CMP)中心并确定其在体内的发育阶段在动力学方面,以及在实验中使用CMRT检测饲喂血管和CMP扩散进入正常组织的扩散边界的方法。试剂包含通式(Fe 3 O 4 + m ⋅的柠檬酸亚铁盐的亚铁磁性纳米粒子的水溶胶(C 6 H 7 O 7 - n。第一种方法涉及合成非化学计量磁铁矿的亚铁磁性纳米晶体,用36%盐酸蚀刻所得的亚铁磁性纳米晶体,从(1.05Fe 2 + O⋅1.85Fe 3 + 2 O 3 ⋅0.1Fe 3 + OCl) m 至(1.15Fe 2 + O⋅1.75Fe 3 + 2 O 3 ⋅0.1Fe 3 + OCl ) m ,然后用柠檬酸根阴离子在含水灰分中涂覆获得的纳米晶体。第二种方法涉及向实验室动物静脉内施用通式(Fe 3 O 4 + )m⋅(C < Sub> 6 H 7 O 7 -)n进行10分钟至75小时,然后进行CMRT扫描检查区域和原发区域CMRT扫描前3–9分钟静脉注射Magnevist ®;以产生T 1 B,T 2 B自旋回波,T 2 B回波梯度和T * 2 B回波梯度;在CMRT扫描被分析的区域之前的3-5分钟,重复静脉注射Magnevist ®并可视化MC扩散进入正常组织的边界,然后二次静脉注射通式化合物的水溶胶( Fe 3 O 4 + )m⋅(C 6 H 7 O < Sub> 7 -)n在CMRT扫描检查区域前5-10分钟,随后可视化MC扩散到正常组织的对比图像;以产生T 1 B,T 2 B自旋回波,T 2 B回波梯度和T * 2 B回波梯度;通过研究区域中体素的强度变化,通过饲喂血管和MC扩散进入正常组织的边界进行CMP鉴定;效果:一组发明提供了阴性和阳性造影剂的组合以及最佳参数CMRT扫描动物的影像检测CMP的机构,早期CMRT检测CMP并通过对不同时期给予CMRT扫描的申报药物进行合成来确定具有可移植性恶性肿瘤的免疫活性动物实验中CMP动力学的发展阶段; 9 cl,14 dwg,2 tbl,8前

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号